Cerebral oxygen metabolism is altered in relapsing-remitting multiple sclerosis (RRMS), possibly a result of disease related cerebral atrophy with subsequent decreased oxygen demand. However, MS inflammation can also inhibit brain metabolism. Therefore, we measured cerebral blood flow (CBF) and cerebral metabolic rate of oxygen (CMRO2) using MRI phase contrast mapping and susceptibility-based oximetry in 44 patients with early RRMS and 36 healthy controls. Cerebral atrophy and white matter lesion load were assessed from high-resolution structural MRI. Expanded Disability Status Scale (EDSS) scores were collected from medical records. The CMRO2 was significantly lower in patients (−15%, p = 0.002) and decreased significantly with age in patients relative to the controls (−1.35 µmol/100 g/min/year, p = 0.036). The lower CMRO2 in RRMS was primarily driven by a higher venous oxygen saturation in the sagittal sinus (p = 0.007) and not a reduction in CBF (p = 0.69). There was no difference in cerebral atrophy between the groups, and no correlation between CMRO2 and MS lesion volume or EDSS score. Therefore, the progressive CMRO2 decline observed before the occurrence of significant cerebral atrophy and despite adequate CBF supports emerging evidence of dysfunctional cellular respiration as a potential pathogenic mechanism and therapeutic target in RRMS.
JennumPWanscherBFrederiksenJ, et al.
The socioeconomic consequences of multiple sclerosis: a controlled national study. Eur Neuropsychopharmacol2012;
22: 36–43.
2.
YsrraelitCCaceresFVillaA, et al.
ENCOMS: Argentinian survey in cost of illness and unmet needs in multiple sclerosis. Arq Neuropsiquiatr2014;
72: 337–343.
3.
DahhamJRizkRKremerI, et al.
Economic burden of multiple sclerosis in low- and Middle-Income countries: a systematic review. Pharmacoeconomics2021;
39: 789–807.
4.
Sastre-GarrigaJParetoDBattagliniM, et al.
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol2020;
16: 171–182.
5.
ComiGRadaelliMSoelberg SørensenP.Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet2017;
389: 1347–1356.
6.
ThompsonAJBaranziniSEGeurtsJ, et al.
Multiple sclerosis. Lancet2018;
391: 1622–1636.
7.
BierhanslLHartungH-PAktasO, et al.
Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov2022;
21: 578–600. doi:10.1038/s41573-022-00477-5.
8.
TrappBDStysPK.Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol2009;
8: 280–291.
9.
PalingDGolayXWheeler-KingshottC, et al.
Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol2011;
258: 2113–2127.
10.
MathurDRodasGLCasanovaB, et al.
Perturbed glucose metabolism: insights into multiple sclerosis pathogenesis. Front Neurol2014;
5: 250–20.
11.
Licht-MayerSCampbellGRCanizaresM, et al.
Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis. Acta Neuropathol2020;
140: 143–167.
12.
RosenkranzSCShaposhnykovAATrägerS, et al.
Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis. Elife2021;
10: 1–60.
13.
PiconePNuzzoD.Promising treatment for multiple sclerosis: mitochondrial transplantation. Int J Mol Sci2022;
23: 2245.
14.
BrooksDJLeendersKLHeadG, et al.
Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. J Neurol Neurosurg Psychiatry1984;
47: 1182–1191.
15.
SunXTanakaMKondoS, et al.
Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med1998;
12: 89–94.
16.
GeYZhangZLuH, et al.
Characterizing brain oxygen metabolism in patients with multiple sclerosis with T2 –Relaxation-Under-Spin-Tagging MRI. J Cereb Blood Flow Metab2012;
32: 403–412.
17.
FanAPGovindarajanSTKinkelRP, et al.
Quantitative oxygen extraction fraction from 7-Tesla MRI phase: reproducibility and application in multiple sclerosis. J Cereb Blood Flow Metab2015;
35: 131–139.
18.
ChoJNguyenTDHuangW, et al.
Brain oxygen extraction fraction mapping in patients with multiple sclerosis. J Cereb Blood Flow Metab2022;
42: 338–348.
19.
de BarcelosIPTroxellRMGravesJS.Mitochondrial dysfunction and multiple sclerosis. Biology (Basel)2019;
8: 37.
20.
AdieleRCAdieleCA.Metabolic defects in multiple sclerosis. Mitochondrion2019;
44: 7–14.
21.
BlinkenbergMJensenCVHolmS, et al.
A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology1999;
53: 149–153.
22.
BlinkenbergMRuneKJensenCV, et al.
Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology2000;
54: 558–564.
23.
DeracheNMariéRMConstansJM, et al.
Reduced thalamic and cerebellar rest metabolism in relapsing-remitting multiple sclerosis, a positron emission tomography study: correlations to lesion load. J Neurol Sci2006;
245: 103–109.
24.
RoelckeUKapposLLechner-ScottJ, et al.
Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology1997;
48: 1566–1571.
25.
BakshiRMiletichRSKinkelPR, et al.
High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging1998;
8: 228–234.
26.
KindredJHTuulariJJBucciM, et al.
Walking speed and brain glucose uptake are uncoupled in patients with multiple sclerosis. Front Hum Neurosci2015;
9: 84.
27.
ZeisTAllamanIGentnerM, et al.
Metabolic gene expression changes in astrocytes in multiple sclerosis cerebral cortex are indicative of immune-mediated signaling. Brain Behav Immun2015;
48: 313–325.
28.
SchiepersCVan HeckePVandenbergheR, et al.
Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler1997;
3: 8–17.
29.
NijlandPGMichailidouIWitteME, et al.
Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions. Glia2014;
62: 1125–1141.
VestergaardMBLindbergUAachmann-AndersenNJ, et al.
Comparison of global cerebral blood flow measured by phase-contrast mapping MRI with 15 O-H 2 O positron emission tomography. J MAGN Reson IMAGING2017;
45: 692–699.
32.
VestergaardMBHenriksenOMLindbergU, et al.
No evidence for direct effects of recombinant human erythropoietin on cerebral blood flow and metabolism in healthy humans. J Appl Physiol (1985)2018;
124: 1107–1116.
33.
JainVLanghamMCWehrliFW.MRI estimation of global brain oxygen consumption rate. J Cereb Blood Flow Metab2010;
30: 1598–1607.
34.
VestergaardMBLarssonHB.Cerebral metabolism and vascular reactivity during breath-hold and hypoxic challenge in freedivers and healthy controls. J Cereb Blood Flow Metab39: 834–848. doi:10.1177/0271678X17737909.
35.
FischlBSalatDHBusaE, et al.
Whole brain segmentation. Neuron2002;
33: 341–355.
36.
ReuterMSchmanskyNJRosasHD, et al.
Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage2012;
61: 1402–1418.
37.
VågbergMGranåsenGSvenningssonA.Brain parenchymal fraction in healthy adults-a systematic review of the literature. PLoS One2017;
12: e0170018.
38.
De StefanoNAirasLGrigoriadisN, et al.
Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs2014;
28: 147–156.
39.
TruckenmillerMENamboodiriMAABrownsteinMJ, et al.
N‐acetylation of L‐aspartate in the nervous system: differential distribution of a specific enzyme. J Neurochem1985;
45: 1658–1662.
40.
AriyannurPSMoffettJRManickamP, et al.
Methamphetamine-induced neuronal protein NAT8L is the NAA biosynthetic enzyme: implications for specialized acetyl coenzyme a metabolism in the CNS. Brain Res2010;
1335: 1–13.
41.
NordengenKHeuserCRinholmJE, et al.
Localisation of N-acetylaspartate in oligodendrocytes/myelin. Brain Struct Funct2015;
220: 899–917.
42.
MoffettJRRossBArunP, et al.
N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol2007;
81: 89–131.
43.
BatesTEStrangwardMKeelanJ, et al.
Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport1996;
7: 1397–1400.
44.
PengSLDumasJAParkDC, et al.
Age-related increase of resting metabolic rate in the human brain. Neuroimage2014;
98: 176–183.
45.
IbarakiMShinoharaYNakamuraK, et al.
Interindividual variations of cerebral blood flow, oxygen delivery, and metabolism in relation to hemoglobin concentration measured by positron emission tomography in humans. J Cereb Blood Flow Metab2010;
30: 1296–1305.
46.
VestergaardMBJensenMLFArngrimN, et al.
Higher physiological vulnerability to hypoxic exposure with advancing age in the human brain. J Cereb Blood Flow Metab2020;
40: 341–353.
47.
AanerudJBorghammerPChakravartyMM, et al.
Brain energy metabolism and blood flow differences in healthy aging. J Cereb Blood Flow Metab2012;
32: 1177–1187.
48.
AttwellDLaughlinSB.An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab2001;
21: 1133–1145.
49.
ZhaoRZJiangSZhangL, et al.
Mitochondrial electron transport chain, ROS generation and uncoupling (review). Int J Mol Med2019;
44: 3–15.
50.
LuFSelakMO'ConnorJ, et al.
Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci2000;
177: 95–103.
51.
Kiryu-SeoSOhnoNKiddGJ, et al.
Demyelination increases axonal stationary mitochondrial size and the speed of axonal mitochondrial transport. J Neurosci2010;
30: 6658–6666.
52.
MahadDJZiabrevaICampbellG, et al.
Mitochondrial changes within axons in multiple sclerosis. Brain2009;
132: 1161–1174.
53.
SadeghianMMastroliaVRezaei HaddadA, et al.
Mitochondrial dysfunction is an important cause of neurological deficits in an inflammatory model of multiple sclerosis. Sci Rep2016;
6: 33249.
54.
PanditAVadnalJHoustonS, et al.
Impaired regulation of electron transport chain subunit genes by nuclear respiratory factor 2 in multiple sclerosis. J Neurol Sci2009;
279: 14–20.
55.
CampbellGRZiabrevaIReeveAK, et al.
Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol2011;
69: 481–492.
56.
CampbellGRMahadDJ.Clonal expansion of mitochondrial DNA deletions and the progression of multiple sclerosis. CNS Neurol Disord Drug Targets2012;
11: 589–597.
57.
CampbellGRReeveAKZiabrevaI, et al.
No excess of mitochondrial DNA deletions within muscle in progressive multiple sclerosis. Mult Scler2013;
19: 1858–1866.
58.
LutzNWViolaAMalikovaI, et al.
Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One2007;
2: e595.
59.
CossuDYokoyamaKSechiLA, et al.
Potential of PINK1 and PARKIN proteins as biomarkers for active multiple sclerosis: a Japanese cohort study. Front Immunol2021;
12: 681386.
60.
PatergnaniSFossatiVBonoraM, et al.
Mitochondria in multiple sclerosis: molecular mechanisms of pathogenesis. Int Rev Cell Mol Biol2017;
328: 49–103.
61.
GebregiworgisTNielsenHHMassilamanyC, et al.
A urinary metabolic signature for multiple sclerosis and neuromyelitis optica. J Proteome Res2016;
15: 659–666.
62.
CampbellGRWorrallJTMahadDJ.The central role of mitochondria in axonal degeneration in multiple sclerosis. Mult Scler2014;
20: 1806–1813.
63.
SmithKJLassmannH.The role of nitric oxide in multiple sclerosis. Lancet Neurol2002;
1: 232–241.
BroholmHAndersenBWanscherB, et al.
Nitric oxide synthase expression and enzymatic activity in multiple sclerosis. Acta Neurol Scand2004;
109: 261–269.
66.
MoncadaSBolañosJP.Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem2006;
97: 1676–1689.
67.
CramerSPSimonsenHFrederiksenJL, et al.
Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. NeuroImage Clin2014;
4: 182–189.
68.
AngleysHØstergaardLJespersenSN.The effects of capillary transit time heterogeneity (CTH) on brain oxygenation. J Cereb Blood Flow Metab2015;
35: 806–817.
69.
LarssonHBWVestergaardMBLindbergU, et al.
Brain capillary transit time heterogeneity in healthy volunteers measured by dynamic Contrast-Enhanced T 1-weighted perfusion MRI. J MAGN Reson IMAGING2017;
45: 1809–1820.
70.
GeraldesRCiccarelliOBarkhofF, et al.
The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol2018;
14: 199–213.
71.
Vidal-JordanaASastre-GarrigaJRoviraA, et al. Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy. 2015.
72.
AndravizouADardiotisEArtemiadisA, et al.
Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Auto Immun Highlights2019;
10: 7.
73.
MadsenSSLindbergUAsgharS, et al.
Reproducibility of cerebral blood flow, oxygen metabolism, and lactate and N-acetyl-aspartate concentrations measured using magnetic resonance imaging and spectroscopy. Front Physiol2023;
14: 1213352–13.
74.
VestergaardMBFrederiksenJLLarssonHBW, et al.
Cerebrovascular reactivity and neurovascular coupling in multiple sclerosis – a systematic review. Front Neurol2022;
13: 912828–15.
75.
ChandlerHLSticklandRCPatitucciE, et al.
Reduced brain oxygen metabolism in patients with multiple sclerosis: evidence from dual-calibrated functional MRI. J Cereb Blood Flow Metab2023;
43: 115–128.
76.
DoluiSWangZWangDJJ, et al.
Comparison of non-invasive MRI measurements of cerebral blood flow in a large multisite cohort. J Cereb Blood Flow Metab2016;
36: 1244–1256.
77.
BesterMForkertNDStellmannJP, et al.
Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients. PLoS One2015;
10: e0119356.
78.
CunniffeNColesA.Promoting remyelination in multiple sclerosis. J Neurol2021;
268: 30–44.
79.
CramerSPModvigSSimonsenHJ, et al.
Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis. Brain2015;
138: 2571–2583.
80.
XuFGeYLuH.Noninvasive quantification of whole-brain cerebral metabolic rate of oxygen (CMRO2) by MRI. Magn Reson Med2009;
62: 141–148.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
